Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Articles|October 1, 2010
- Applied Clinical Trials-02-01-2010
- Volume 0
- Issue 0
Applied Clinical Trials Digital Edition - October 2010
REGULATORY : Is It Safe to Outsource Safety? Waiving Inclusion/Exclusion Criteria CRO/SPONSOR : Metrics - The Pitfalls of Over Collection SUBJECT RECRUITMENT : Trial Results Provided to Volunteers in Pilot Program Also in this issue : New Reform Law Requires Fee Disclosure, GCP Standards in Global Trials, A Learning Healthcare System, The Physician Payments Sunshine Act
Advertisement
Articles in this issue
almost 17 years ago
Applied Clinical Trials Digital Edition - February 2010almost 17 years ago
Prepare Early for Adverse Eventsalmost 17 years ago
Paying the Phase I Volunteeralmost 17 years ago
When Great Ideas Meet the Real Worldalmost 17 years ago
Business and People Update February 2010almost 17 years ago
Science and Research Top FDA Prioritiesalmost 17 years ago
EMEA Sees Benefits for Childrenalmost 17 years ago
Aging Under the Microscope in Europealmost 17 years ago
How to Improve Children's Researchalmost 17 years ago
Cardiovascular Drug ActivityAdvertisement
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
What Needs to Happen Beyond the Clinical Trial Modernization Act
2
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance
5